Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

John B.A.G. Haanen(Leiden University Medical Center), Michel Obéid(University of Lausanne), Alexander M. Menzies(The University of Sydney), Petros Grivas(Seattle Cancer Care Alliance), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Solange Peters(University Hospital of Lausanne), James Larkin(Trinity College Dublin), Marc S. Ernstoff(National Cancer Institute), Yinghong Wang(Hangzhou Center for Disease Control and Prevention)
Journal for ImmunoTherapy of Cancer
June 1, 2020
10.1136/jitc-2020-000604
Cited by 164

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k